There remains clinical equipoise in the appropriate selection of antiplatelet therapy for the patient on long-term anticoagulation requiring percutaneous coronary intervention. Since most of these patients represent an increasingly aging population, the significant risk of thromboembolism and stent thrombosis must be weighed against the risk of major bleeding. This article reviews the current state of evidence to provide a framework for the practicing clinician.
Keywords: Dual antiplatelet therapy (DAPT); Oral anticoagulants (OAT); Percutaneous coronary intervention (PCI); Triple antithrombotic therapy (TOAT).
Published by Elsevier Inc.